I think rebranding is a waste of time, we all have called Leronlimab by that name through a couple of name changes including Livimmune. If we partner, then we change the name of the drug or combo for that indication, but at this point I don't see a gain. If you want to get away from the past, change the name of the company, but even that seems like a waste of time. All MAB's have that mab ending, so until you are going to put it on the shelf for consumers, we are selling the drug as an MAB, when it goes to distribution you come up with a cute name that is appropriate. If we partner with big pharma, I'm sure they'll come up with something.